Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$2.47 USD
+0.14 (6.01%)
Updated Aug 11, 2025 04:00 PM ET
After-Market: $2.46 -0.01 (-0.40%) 5:30 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AUTL 2.47 +0.14(6.01%)
Will AUTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AUTL
Autolus Therapeutics Q2 2025 Earnings Preview
Autolus Therapeutics PLC (AUTL) Q2 2025 Earnings Report Preview: What To Look For
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call ...
Analyst Reiterates Buy Rating on Autolus Therapeutics (AUTL) | AUTL Stock News